Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 3/20 | 0.60 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.60 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8949694 | 0.86 | CACNA1F (0.64) | CACNA1FCACNA1DCACNA1SCACNA1CPTPN1 | |
| SCHEMBL2648819 | 0.85 | CACNA1F (0.70) | CACNA1FCACNA1DCACNA1SCACNA1CKMT2A | |
| SCHEMBL2647704 | 0.85 | CACNA1F (0.56) | CACNA1FCACNA1DCACNA1SCACNA1CPTPN1 | |
| SCHEMBL9229958 | 0.84 | CACNA1F (0.59) | CACNA1FCACNA1DCACNA1SCACNA1CPTPN1 | |
| SCHEMBL2647640 | 0.83 | CACNA1F (0.44) | CACNA1FCACNA1DCACNA1SCACNA1CPTPN1 | |
| SCHEMBL8193038 | 0.83 | CACNA1F (0.57) | CACNA1FCACNA1DCACNA1SCACNA1CPTPN1 | |
| SCHEMBL9382997 | 0.82 | KDM4E (0.48) | CACNA1FCACNA1DCACNA1SCACNA1CPTPN1 | |
| SCHEMBL9803685 | 0.82 | CACNA1F (0.56) | CACNA1FCACNA1DCACNA1SCACNA1CPTPN1 | |
| SCHEMBL9744040 | 0.81 | CACNA1F (0.45) | CACNA1FCACNA1DCACNA1SCACNA1CPTPN1 | |
| SCHEMBL27310185 | 0.80 | CACNA1F (0.52) | CACNA1FCACNA1DCACNA1SCACNA1CPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1162197-B1 | Process for the preparation of pyridines by oxidation of dihydropyridines using methyl nitrite | BAYER CHEMICALS AG (DE) | 2004-05-26 | — | — | EP | claimed |
| US-6392050-B2 | REACTING 1,4-DIHYDROPYRIDINE WITH METHYL NITRITE IN PRESENCE OF ACID CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-21 | — | — | US | claimed |
| US-20020002285-A1 | Process for preparing substituted pyridines | BAYER AKTIENGESELLSCHAFT (DE) | 2002-01-03 | — | — | US | claimed |
| US-6392050-B2 | REACTING 1,4-DIHYDROPYRIDINE WITH METHYL NITRITE IN PRESENCE OF ACID CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-21 | — | — | US | disclosed |
| US-20020002285-A1 | Process for preparing substituted pyridines | BAYER AKTIENGESELLSCHAFT (DE) | 2002-01-03 | — | — | US | disclosed |
| US-4950675-A | ANTICHOLESTEROL AGENTS | WARNER-LAMBERT COMPANY (US) | 1990-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002285-A1 | Process for preparing substituted pyridines | QDPR, NOX4, NOX5 | CACNA1F 1140/4885CACNA1D 1278/4885CACNA1S 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.